Ebetuel Pallares Net Worth

The estimated Net Worth of Ebetuel Pallares is at least $451 mil dollars as of 11 March 2020. Ebetuel Pallares owns over 24,692 units of Exagen Inc stock worth over $437,068 and over the last 5 years he sold XGN stock worth over $0. In addition, he makes $14,375 as Independent Director at Exagen Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ebetuel Pallares XGN stock SEC Form 4 insiders trading

Ebetuel has made over 1 trades of the Exagen Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 24,692 units of XGN stock worth $45,433 on 11 March 2020.

The largest trade he's ever made was exercising 24,692 units of Exagen Inc stock on 11 March 2020 worth over $45,433. On average, Ebetuel trades about 3,527 units every 0 days since 2019. As of 11 March 2020 he still owns at least 144,247 units of Exagen Inc stock.

You can see the complete history of Ebetuel Pallares stock trades at the bottom of the page.

Ebetuel Pallares biography

Dr. Ebetuel Pallares serves as Independent Director of the Company. Dr. Pallares founded Proficio Capital Management (PCM), LLC, a seed and early-stage venture fund headquartered in El Paso, TX, and he has served as its General Partner since that time. Through PCM, Dr. Pallares manages several investments, including PCM/Exagen L.P. In June 2009, he co-founded Cottonwood Capital Partners, the general partner of Cottonwood Technology Fund, a seed and early-stage venture fund with headquarters in El Paso, Texas, and he served as its Managing Partner until December 2014. In 2006, Dr. Pallares founded Joseph Advisory Services, LLC, a strategic consulting firm, and has served as its Manager since that time. He also currently manages investments on behalf of a family office, managing fund commitments and direct investments into private operating companies. His investment sectors span healthcare, medical diagnostics, therapeutics, IT, materials sciences and nanotechnology, education technology, AR/VR and financial technology companies. Dr. Pallares also serves on several corporate and non-profit boards, as an advisor to the UT Horizon Fund, the venture capital investment fund of the University of Texas system, as an Investor in Residence for New Mexico State University’s Arrowhead Center and on the limited partnership advisory committee for several venture funds. Dr. Pallares’s extensive venture capital experience and his service as a director for numerous companies contributed to our Board's conclusion that he should serve as a director of our company.

What is the salary of Ebetuel Pallares?

As the Independent Director of Exagen Inc, the total compensation of Ebetuel Pallares at Exagen Inc is $14,375. There are 10 executives at Exagen Inc getting paid more, with Fortunato Rocca having the highest compensation of $1,627,720.

How old is Ebetuel Pallares?

Ebetuel Pallares is 46, he's been the Independent Director of Exagen Inc since 2012. There are 11 older and 3 younger executives at Exagen Inc. The oldest executive at Exagen Inc is James Tullis, 72, who is the Independent Director.

What's Ebetuel Pallares's mailing address?

Ebetuel's mailing address filed with the SEC is C/O EXAGEN INC., 1261 LIBERTY WAY, VISTA, CA, 92081.

Insiders trading at Exagen Inc

Over the last 5 years, insiders at Exagen Inc have traded over $8,628,989 worth of Exagen Inc stock and bought 556,568 units worth $6,283,309 . The most active insiders traders include James L L Tullis, Bio Exagen, L.P.H.I.G. Gpii..., eJeffrey Thomas Elliott. On average, Exagen Inc executives and independent directors trade stock every 48 days with the average trade being worth of $109,189. The most recent stock trade was executed by John Aballi on 16 May 2024, trading 40,401 units of XGN stock currently worth $77,570.

What does Exagen Inc do?

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.

Complete history of Ebetuel Pallares stock trades at Exagen Inc

Exagen Inc executives and stock owners

Exagen Inc executives and other stock owners filed with the SEC include:

• Fortunato Rocca,
  President, Chief Executive Officer and Director
• Fortunato Rocca,
  CEO, Pres & Director
• Kamal Adawi M.S., MBA,
  CFO & Corp. Sec.
• Dr. Debra Jeske Zack,
  Chief Medical Officer
• Kamal Adawi,
  Chief Financial Officer and Corporate Secretary
• Jeffrey Elliott,
  Independent Director
• Tina Nova,
  Independent Director
• Chet Burrell,
  Independent Director
• Brian Birk,
  Independent Chairman of the Board
• Bruce Robertson,
  Independent Director
• James Tullis,
  Independent Director
• Ebetuel Pallares,
  Independent Director
• Wendy Johnson,
  Independent Director
• Debra Zack,
  Chief Medical Officer
• Anja Kammesheidt,
  Chief Scientific Officer
• John Wegener,
  Sr. VP of Sales and Marketing
• Dr. Ming-Chou Lee Ph.D.,
  Chief Technology Officer
• Mark Hazeltine,
  Chief Operating Officer
• Frank Stokes,
  Director
• Scott D Kahn,
  Director
• Thierry Dervieux,
  Chief Scientific Officer
• James L Ltullis Growth Fund...,
  
• Bio Exagen, L.P.H.I.G. Gpii...,
  
• Dickerson Capital Focus Iii...,
  
• Holdings Limited Partnershi...,
  
• Co Investment Fund, L.P.Nms...,
  
• Paul Kim,
  Director
• Co Investment Fund, L.P.Sun...,
  
• Ana Hooker,
  Director
• John Aballi,
  President and CEO
• Mark Hazeltine,
  Chief Business Officer
• Jeffrey G. Black,
  Chief Financial Officer